During morning rounds in the medical intensive care unit, a physician evaluates a 74-year-… — USMLE Step 3

During morning rounds in the medical intensive care unit, a physician evaluates a 74-year-old woman who is being treated for severe community-acquired pneumonia and sepsis. She has a known history of focal impaired awareness seizures, which are normally well-controlled on oral phenytoin. However, due to intubation and enteral feeding intolerance upon admission three days ago, she was transitioned to an intravenous maintenance dose of phenytoin. Today, she has been successfully extubated but appears lethargic and confused. Neurologic examination reveals prominent bilateral horizontal nystagmus, dysarthria, and wide-based truncal ataxia when she is assisted to the edge of the bed.

Morning laboratory results are as follows:

Test	Result
Sodium	138 mEq/L
Potassium	4.1 mEq/L
Blood urea nitrogen	18 mg/dL
Creatinine	0.9 mg/dL
Albumin	2.0 g/dL

A total serum phenytoin concentration obtained two hours prior to the next scheduled dose is 15 mcg/mL (reference range: 10-20 mcg/mL).

Which of the following is the most appropriate next step in the management of this patient?

Hold the phenytoin infusion and order a free serum phenytoin levelAnswer
B
Continue the current medication regimen as the drug concentration is within the therapeutic window
C
Add intravenous valproic acid for enhanced seizure prophylaxis
D
Administer intravenous haloperidol to manage suspected intensive care unit delirium
E
Order an urgent magnetic resonance imaging of the brain without contrast

Answer

Hold the phenytoin infusion and order a free serum phenytoin level.

Phenytoin is a highly protein-bound antiepileptic drug, with approximately 90% typically bound to serum albumin. The standard laboratory assay measures *total* phenytoin, which encompasses both the bound (inactive) and unbound (active, or 'free') fractions. The established normal therapeutic range for total phenytoin is 10-20 mcg/mL. However, in patients with significant hypoalbuminemia (albumin < 3.2 g/dL), such as this critically ill patient, there is a deficit of albumin available for binding. This leads to a substantial increase in the fraction of free, pharmacologically active phenytoin, even when the total level appears normal.

To estimate the true biologically active concentration, the Winter-Tozer equation is applied for patients with normal renal function:

C_{adjusted} = \frac{C_{total}}{(0.2 \times \text{Albumin}) + 0.1}

For this patient, the adjusted total phenytoin calculation yields:

C_{adjusted} = \frac{15}{(0.2 \times 2.0) + 0.1} = \frac{15}{0.4 + 0.1} = \frac{15}{0.5} = 30 \text{ mcg/mL}

An adjusted equivalent level of 30 mcg/mL is severely toxic. The patient's clinical presentation of lethargy, prominent bilateral horizontal nystagmus, dysarthria, and truncal ataxia directly reflects acute phenytoin toxicity. Therefore, the most appropriate next step in management is to immediately hold the phenytoin infusion and order a direct free serum phenytoin level (therapeutic range typically 1-2 mcg/mL) to accurately monitor her status and guide future dosing adjustments.

Step-by-Step Solution

Evaluate the clinical presentation and neurologic examination.

The patient exhibits lethargy, bilateral horizontal nystagmus, dysarthria, and ataxia.

These findings represent the classic clinical triad of acute phenytoin toxicity.

Analyze the laboratory data in the context of the patient's medications.

The total serum phenytoin is 15 mcg/mL (normal range), but the serum albumin is significantly low at 2.0 g/dL.

Phenytoin is highly protein-bound (approximately 90%). Total phenytoin levels measure both bound and unbound fractions. In hypoalbuminemia, there is less protein available, increasing the free, pharmacologically active fraction.

Calculate the adjusted total phenytoin level to estimate true toxicity.

Using the Winter-Tozer equation: Adjusted Level = 15 / ((0.2 * 2.0) + 0.1) = 15 / 0.5 = 30 mcg/mL.

An adjusted total level of 30 mcg/mL is well above the therapeutic maximum of 20 mcg/mL, chemically confirming the clinical diagnosis of severe toxicity.

Determine the best next step in monitoring and treatment evaluation.

The correct action is to immediately withhold the offending medication and order a direct laboratory measurement of the active component.

Holding the dose prevents further neurotoxicity, and measuring the free phenytoin level (therapeutic range 1-2 mcg/mL) provides an accurate baseline to safely restart and adjust dosing once toxicity resolves.

Key Concept

In patients with significant hypoalbuminemia, highly protein-bound drugs like phenytoin will have a higher free (active) fraction. A standard total phenytoin level may appear falsely normal, necessitating the calculation of an adjusted level or the direct measurement of free phenytoin to avoid and manage toxicity.

Question

Answer

Step-by-Step Solution

Key Concept

Common Mistakes

Topics

More questions from this topic